🌍·10h agodiscovery
U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia
Publisher
P
PR Newswire
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- PR Newswire
- Region
- Global
- Scope
- discovery
- Published
- July 13, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on news.google.com
Leave the platform to read the original full article on the publisher site.
Source: PR Newswire
Scope: discovery
Related coverage
More related coverage
Investing.com/7h ago
BofA raises Krystal Biotech stock price target on Vyjuvek growth
European Biotechnology Magazine/7h ago
CriteriaCaixa targets €300M for biotech and tech by 2030
PUNE PULSE/7h ago
Pune: FDA Seizes Suspected Adulterated Food Stock Worth ₹37.61 Lakh Across Seven Locations
The Pharma Letter/7h ago